Article

CK effects, results may be temporary

Author(s):

Stanford, CA-Refractive surgeons performing conductive keratoplasty (CK, Refractec) for correction of mild to moderate hyperopia can expect good visual results initially, but they should warn patients that CK effects might not be permanent, explained Jason S. Ehrlich, MD, PhD.

Dr. Ehrlich and his co-author, Edward E. Manche, MD, both of Stanford University School of Medicine, Stanford, CA, undertook a prospective, non-randomized clinical study to determine the long-term safety and efficacy of radiofrequency energy for the correction of hyperopia between +0.75 and +3.00 D sphere and ≤75 D cylinder in 14 patients (25 eyes). The mean patient age was 55.4 years, Dr. Ehrlich reported.

Patients were treated at the peripheral corneal stroma with the NearVision CK probe (Refractec).

Dr. Ehrlich then presented the long-term results of CK in his cohort of 11 eyes of seven patients who had been followed for an average of 55.3 months (range, 37 to 75 months). Preoperatively, patients had a mean MRSE of +1.47 D and at 24 months follow-up, the mean MRSE was 0.57 D. These results were similar to those published in 2003, Dr. Ehrlich said.

"As we get close to 60 months (follow-up), there is significant regression toward the preoperative SE refraction," Dr. Ehrlich pointed out. The mean MRSE was +1.23 D at 55.3 months.

By the last follow-up, UCVA of >20/20 was seen in 27% of the patients, >20/30 UCVA in 64% of patients, and <20/40 UCVA in 36%. One patient developed a cataract, yet no patient experienced >0.75 D of induced cylinder, he said.

There were some limitations to the study. "Obviously it is a single-surgeon study in a single center with a relatively small number of patients," Dr. Ehrlich pointed out. "We are not evaluating the Light Touch technique, and we have not stratified our results by preoperative central or peripheral corneal thickness, which may influence stability of treatment."

Although CK for mild to moderate hyperopia seems to be safe and effective initially, its results should be viewed as temporary because of regression toward the preoperative baseline when followed for 5 years, Dr. Ehrlich said.

Dr. Ehrlich is continuing to gather long-term follow-up data on additional patients. His report was submitted for peer-review publication.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.